【摘要】 目的　研究 VAM方案作为二线方案治疗耐药卵巢癌的疗效和毒性反应。方法　长春酰胺、阿克拉霉素、丝裂霉素联合应用治疗 2 5例经铂类化疗失败的卵巢癌。结果　完全缓解 3例 ,部分缓解 5例 ,总有效率为 32 .0 % (8/ 2 5 )。对铂类难治性患者、铂类耐药者和敏感者有效率分别为18.2 %、2 8.6 %和 5 7.1%。毒性反应以骨髓抑制为明显 , + 度白细胞、中性粒细胞和血小板下降分别为 40 .0 %、6 0 .0 %和 2 8.0 %。胃肠反应、心脏、神经毒性均不严重 ,脱发占 32 .0 %。结论　 VAM方案是当前国内治疗耐铂卵巢癌切实可行的有效方案 ,值得推广应用更多还原

【Abstract】 Objective To study the response rate and toxic side effect of Vindesine, aclarubicin and mitomycin (VAM) as a new regime of second line chemotherapy for ovarian carcinoma refractory to platinum group of drugs.Methods From June 1997 through August 1998, 25 cases of refractory ovarian carcinoma were treated with VAM regime. The response rate and the side reactions were analyzed. Results The overall response rate was 32.0%, with 3 complete response (CR) and 5 partial response (PR). In the platinum refractory, platinum resistant platinum senstitive strata, the response rates were 18.2% 28.6% and 57.1% respectively. Myelosuppression was the main toxic effect. Grade 3 and grade 4 neutropenia occurred in 40.0% and thrombocytopenia in 28.0% of the patients. Alopecia occurred in 32% of cases. Gastrointastinal, cardiac and neurologic toxicities were mild. Conclusion VAM regime is a practical and effective second line chemotherapy for patients with ovarian carcinoma refractory to platinum based chemothrapy.更多还原